Showing 3571-3580 of 5062 results for "".
Can UV Nail Dryers Cause Skin Cancer?
https://practicaldermatology.com/topics/hair-nails/can-uv-nail-dryers-cause-skin-cancer/23898/Alexis Livingston Young, MD, weighs in on the evidence.Thick Melanomas: Assessing Prognosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/thick-melanomas-assessing-prognosis/23685/New data identifies stratified risk based on the thickness of melanomas thicker than 4mm.Are You Down with QPP?
https://practicaldermatology.com/topics/practice-management/are-you-down-with-qpp/20853/The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Update on Pediatric Psoriasis
https://practicaldermatology.com/columns/clinical-focus-1/update-on-pediatric-psoriasis/23358/New guidelines and new treatments seek to dramatically improve lives of children with psoriasis.Melanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.RIP MU?
https://practicaldermatology.com/topics/practice-management/rip-mu/21010/Five ways to prepare for whatever comes next.The Melanoma Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-melanoma-pipeline/21400/A closer look at the latest data for two investigational agents that have made headlines.Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.Icotrokinra and the Oral Therapy Revolution
https://practicaldermatology.com/topics/psoriasis/icotrokinra-and-the-oral-therapy-revolution/60986/Icotrokinra is the only commercially available therapy that selectively blocks the receptor of IL-23 rather than the IL-23 cytokine.